Elevation and fluctuation of serum CA 19-9 and SPAN-1 levels after administration of sulfonylurea in a diabetic patient with Lewis(a-,b-) blood phenotype.
Yoshioka
K
K
D000951:Antigens, Neoplasm / Q000097:blood*; D001786:Blood Glucose / Q000378:metabolism; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005907:Gliclazide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D007983:Lewis Blood Group Antigens; D008875:Middle Aged; D013997:Time Factors
D000951:Antigens, Neoplasm; D001786:Blood Glucose; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D005907:Gliclazide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D007983:Lewis Blood Group Antigens; C059729:pancreatic associated antigen, SPan-1